Program
elebsiran
Also written as “VIR-2218”, “Elebsiran” and “BRII-835 (VIR-2218)”.
Its studies are mostly in Hepatitis B, Chronic · Hepatitis · Renal Insufficiency · Fibrosis · Hepatitis D, Chronic, led by 3 companies.
Drug pageElebsiran: every studyAll 12 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Vir Biotechnologyits history only | 84 open or running | phase 3since Mar 24, 2025 | Sep 11, 2018 | Dec 2026phase 3 · NCT07128550 |
| Brii Biosciences | 20 open or running | phase 2since Aug 7, 2020 | Aug 7, 2020 | none ahead |
| Virion Therapeuticsits history only | 10 open or running | phase 1since Sep 20, 2023 | Sep 20, 2023 | none ahead |
Also a collaborator on its studies: VBI Vaccines and Alnylam Pharmaceuticals.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Brii Biosciences only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.
- Aug 7, 2020First study: phase 2 study in Hepatitis B, ChronicFirst studyNCT04507269 · 21 enrolled · China
- Feb 7, 2021Phase 2 study in Hepatitis B, ChronicNCT04749368 · 91 enrolled · Australia, China, New Zealand and more
- Jul 21, 2022Named elebsiranINNProposed as its International Nonproprietary Name in WHO's List 127 · before, VIR-2218
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 2 Brii Biosciences leads, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT04749368Hepatitis B, Chronic · Australia, China, New Zealand and more | 2 | Completed | Jul 4, 2023 | 91 |
| NCT04507269Hepatitis B, Chronic · China | 2 | Completed | Sep 30, 2021 | 21 |
How it is read
Names in the registry
- “VIR-2218”, 7 entries
- “Elebsiran”, 3 entries
- “BRII-835 (VIR-2218)”, 1 entry
Conditions, from the studies’ own filings
- Hepatitis B, Chronic, 5 studies
- Hepatitis, 3 studies
- Renal Insufficiency, 1 study
- Fibrosis, 1 study
- Hepatitis D, Chronic, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.